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Abstract 
The definition and factors of extended criteria donors have already been set, however details of 
the various opinions still differ in many respects. In this review, we summarize the impact of 
these factors and their clinical relevance. Elderly livers must not be allocated for hepatitis C virus 
(HCV) positives, or patients with acute liver failure.  In cases of markedly increased serum 
transaminases, donor hemodynamics is an essential consideration. A prolonged hypotension of 
the donor does not always lead to an increase in post-transplantation graft loss if postOLT care is 
proper. Hypernatremia of less than 160 mEq/L is not an absolute contraindication to accept a 
liver graft per se. The presence of steatosis is an independent and determinant risk factor for the 
outcome. The gold standard of the diagnosis is the biopsy. This is recommended in all doubtful 
cases. The use of HCV+ grafts for HCV+ recipients is comparable in outcome. The leading risk 
factor for HCV recurrence is the actual RNA positivity of the donor. The presence of a proper 
anti-HBs level seems to protect from de novo HBV infection. A favourable outcome can be 
expected if a donation after cardiac death liver is transplanted in a favourable condition, meaning, 
a warm ischemia time < 30 minutes, cold ischemia time < 8–10 hours, and donor age 50–60 
years. The pathway of organ quality assessment is to obtain the most relevant information (e.g. 
biopsy), consider the co-existing donor risk factors and the reserve capacity of the recipient, and 
avoid further technical issues. 
I) Introduction 
The use of extended criteria donors (ECD) became an acceptable compromise in liver 
transplantation (OLT). Unnecessary refusal of potential donor livers was reported more than a 
decade ago [1]. How should the advantages and disadvantages of extended criteria donors be 
measured?  Is waitlist mortality (WLM), versus the cumulative, patient and graft survival a the 
measurable cornerstone? Are the definitions of ECD homogenous? We reviewed the literature 
surrounding this topic. The main issues were to focus on the main parameters, like graft steatosis, 
donor age, hepatitis C virus, and hepatitis B virus positive grafts, as well as DCDs. No unique 
parameter exists that is relevant to assess the quality of a donor liver.  The factors can be divided 
into donor parameters, logistical parameters, and recipient factors. In order to assess the EC, the 
donor age, and liver function tests, are the first, basic filters, which will be followed by the donor 
management parameters, like ventilation time, the amount of catecholamines, circulatory 
instability, and temporary cardiac arrest. The assessment of steatosis is useful, and important, but 
the feasibility of a mandatory biopsy is questionable. Organ shortage provoked to accept 
HBV/HCV positive, and CDC donor livers. We discuss the experience about these factors in the 
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relevant literature.  The outcome parameters and survival results are discussed in the second 
chapter of the review.  
II) Background 
Definition, categorization, and factors of extended criteria donors were already set in 2007 by 
Barshes, Nickkholgh, the Heidelberg group, Northup, and others[2,3,4].  The composites of these 
definitions are summarized on Table 1. Other studies revealed on a similar criterion like Schemmer 
et al [5], and Afonso et al [6]. Finally the Paris-consensus meeting with the contribution of experts 
from Europe, the United States, and Asia declared that donor quality represents a continuum of 
risk rather than "good or bad”, declaring that using an ECD is needed, even if it generates 
increased morbidity and mortality [7]. An ideal donor is different from an ideal graft, because 
CIT, or technical variants, such as split-liver allograft might also have an influence. After the 
publication of the Paris-consensus meeting, the ECD definition was mainly confined to the direct 
donor factors to assess the risk at the time of procurement. The Donor Risk Index (DRI) was 
established by Feng S to help assess the risk for a given donor [8], however it does not take 
steatosis intoaccount, but the donor’s age, race, height, and COD; the split liver donation status; 
the DCD status; the type of allocation (local, regional, or national); and the CIT are included. 
This is also seen in Table 1, that the approach to ECD has moved from age, to allocation, and 
steatosis. Among European or Asian populations, some variables such as African-American or 
regional sharing versus national sharing are not relevant [7]. The quality of a donor liver has a 
strong correlation with the incidence of the early allograft dysfunction (EAD), or initial poor 
function (IPF). Definition varies, can be established by the recovery of hepatocytes [9] as ALAT 
and/or ASAT above 1500 IU/L within 72 hours after OLT. Also detoxication, and synthetic 
function can be measured [10] when IPF is declared if the quotient of spontaneous prothrombin 
(PT) time and serum bilirubin is <1 on the day 5th after OLT. Lucidi V et al [11] combine the 
two: Others declare IPF as good, fair, or poor function according to the ASAT and PT over the 
first 5 days [12]. Müllhaupt et al divided risk factors as donor, and transplant ones. Donor non-
Caucasian race, and CVA (as COD) are given, while donor BMI, and diabetes were found not be 
significant risk factors [13]. Feng et al evaluated the data of 20 000 donors in 2006: age, race, 
donor height, CVA (as COD), and partial/split graft independently increased the risk for graft 
failure.  Donors with a prolonged ICU management (>7 days), cardiopulmonary resuscitation, 
and use of inotropes rescued for an infection [8]. 
Others did not find adverse outcomes if the recipient received a graft from an infected donor 
[14]. With respect to grafts from donors with central nervous system malignancy (CNS) it was 
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reported that in 179 cases of liver grafts from CNS donors, only 1 (0,55%) transmission was 
observed to the recipient. These donors can be used in fully informed patients who have a high 
risk of death without an OLT [15].  
Burroughs et al revised the overall UCLA experience (10000 allografts) in 2009. Significant factors 
with multivariate analysis were; donor hospital stay >5 days, donor age >55 years old, CIT >12 h, 
and WIT >40 min [16]. Results of the University of Montreal concluded on 634 grafts to 634 
recipients (52,8% had at least 1 ECD score), that factors associated with graft survival were the 
graft gross appearance (P < 0.001), the donor partial pressure of oxygen/fraction of inspired 
oxygen ratio (less than 300 mm Hg), and the donor haemoglobin level (higher than 100 g/L;). 
[17].  
Factors for a graft failure were divided into those for the recipient (HCV positivity, any diagnosis 
with malignancy, previous OLT, a BMI>30) and those for the donor (anti-HBc positivity, arterial 
pressure < 60 mm Hg for > 20 min., and CIT > 6 hours). The 5-years graft survival was 83% in 
the low risk (ECD 0-1) group vs 62% in the intermediate (ECD 2-4), and  0% high risk (ECD 
>4) group [18]. A recent large study by  European Liver Intestine Transplant Association 
(ELITA) and Eurotransplant Liver Intestine Advisory Committee (ELIAC) reports more than 
50% incidence of ECDs in ET in 2012 [19]. They enrolled all 6621 OLTs performed within ET, 
and validated the DRI developed by OPTN, for the ET as well. The following criteria are being 
used as risk factors within the ET group: a donor age > 65 years; ICU  stay >7 days; high BMI; 
steatosis; hypernatremia; high levels of ASAT, ALAT, and serum bilirubin. Among all donors, 
transplants and recipient variables used in the ET, finally the DRI was the strongest predictor of 
the outcomes [19]. A very similar approach, within the framework of European Liver Transplant 
Registry (ELTR) was published: in the multivariate analysis of 4701 donor’s data, CIT, highest 
sodium, COD, gamma glutamyl transferase  (γGT), and donor sex (female) were statistically 
significant factors for 3 months, and CIT, γGT, and COD for 12-month survival. The median 
DRI of this study population was 1.45 [20]. 
The results of the ELITA-ELTR questionnaire about ECD definitions of 35 OLT centres are: 
steatosis in 94% of centres; age up to 80 years (43%); serum sodium >165 mmol/L (71%); ICU 
stay with ventilation > 7 days (48%); ASAT >90 U/L, (17%); BMI >30 in 54%); ALAT >105 
U/L (23%); serum bilirubin >3 mg/dL (43%); and all criteria together in 2 centres (6%) [21]. 
Arjona-Sanchez et al suggested a prediction model to discard á priori liver grafts by three variables: 
age, pathological ultrasonography, and BMI >30. The area under curve was 82.7%, and for a 
probability to discard of 70%, the false-positive probability was 1.2% [22]. 
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In conclusion when talking about ECD, we should mention donor age, abnormal liver function 
tests, hypernatremia, steatosis of the donor liver, prolonged ICU stay, the use of vasopressors, 
resuscitation and donors with HCV/HBV positivity as a minimal consensus that has not changed 
since 2007. It has been demonstrated that DCD or non-heart beating donors (NHBD), and 
macrosteatosis of the graft liver must be considered as separate risk factors, inducing graft 
dysfunction and increased injury post-LT. Macrovesicular steatosis is characterized by a single fat 
vacuole larger that nucleus, which displaces the nucleus to the periphery. Its grade correlates with 
the incidence and severity of graft dysfunction.  It is debatable to define split (reduced size) liver 
grafts as ECD or not. In summary, the elements of discussion are the conventional and non-
conventional risk factors of ECD. 
III) Conventional factors of an Extended Criteria Donor 
This chapter briefly discusses conventional” ECD parameters. These are the donor age, abnormal 
liver function tests, circulatory instability in a brain death donor (or temporary cardiac arrest), 
alcohol abuse, infection of the donor, hypernatremia and liver steatosis. We call them 
conventional since they were involved in the assessment of all (also non-ECD) donors from the 
beginning. 
1) Donor age  
The age is a relevant factor [23,24], that has steadily increased: in 1994 only 20% of donors were 
50 years or older, and it has doubled till today in the US [13]. The annual number of donors aged 
>65 years has been increased 14-fold between 1991 to 2001 in the UNOS database, and the rate 
of donors >60 years increased from 2% to 20% in the ELTR [3]. Routine liver function tests do 
not show age-associated changes, hepatic flow decreases about 35%–40% and bile flow about 
50%, reflecting at least in part, impairment of energy-dependent and microtubule-dependent 
transport processes. The cytochrome P450 content of liver specimens is recently reported to 
decline from the age of 40 to 69 years by 16% and further decline by 32% over age of 70. 
However this paradigm shift has not negatively impacted graft or patient survival [23]. The Paris 
consensus meeting reported that there is no absolute limit of donor age for liver transplantation, 
however it is strongly recommended not to allocate elderly donors to HCV-infected recipients 
[7], since a donor age between 61-70 gives a relative risk 1,53 (Odds Ratio) for HCV recurrence, 
while it is 1.65 over 70 years of age [13]. Others did not confirmed donor gender as a risk factor 
[13], and successful utilization of liver graft from donors older than 80 years of age are published 
[24]. In contrast Serrano et al reported an increased risk of non-anastomotic biliary stricture in case 
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of donors>60 years of age [25], which is in accordance with a recent nationwide German 
multicentre study [26]. Kim DY et al identified recipient HCV positivity, model for end stage liver 
disease (MELD) >20, donor serum glucose > 200 mg/dL, and more than 40 minutes to aortic 
crossclamp in donor surgery, as risk factors in addition to donor age > 65 years. The 5 years graft 
survival rates, having 0, 1, 2, 3, and 4 unfavourable characteristics were 100%, 82.0%, 81.7%, 
39.3%, and 25.0%, respectively (p < 0.05). A good graft survival can be achieved using elderly 
donor liver allografts with appropriate recipient selection, donor blood glucose management and 
efficient liver recovery with minimal manipulation of the liver during donor surgery [27]. An 
additive risk factor is the transmission of malignancies since the high incidence of unrecognized 
malignancies in the elderly [28]. In a recent retrospective, single centre study 10% of recipient had 
a liver from a donor older than 80 years. There was no difference in terms of early (≤30 days) 
graft loss but, the 5-year graft survival was lower for HCV-positive versus HCV-negative 
recipients (62.4% vs. 85.6) in the group ≥80 years [29]. In conclusion we can say that the age of 
reported donors increases with time. Age should not be considered as an independent risk factor, 
only if that occurs  in parallel with some others. An elderly liver must not be allocated for HCV 
positive recipients, or patients with an acute liver failure, but they can be used safely for other 
indications 
2) Abnormal liver function tests 
There is no clear upper limit in serum transaminases that is a contraindication. [13]. The elevated 
LFTs are not specific. They represent a certain problem, but do not give a key to the problem 
itself: that can be HCV infection, ischemia injury, steatosis, temporary circulatory arrest etc. Also 
a, normal or near normal liver function test is not a guarantee that there are no significant 
parenchymal lesions. In cases of markedly increased serum transaminases, donor hemodynamics 
is an essential consideration. During the Paris consensus meeting in 2008, it was also agreed that 
in the case of a marked increase in the γGT level, and/or an increased international normalized 
ratio (INR), the other donor factors, including a history of alcohol abuse and non-alcoholic 
steatohepatitis (NASH), should be carefully assessed before procurement is considered, and .a 
liver biopsy is warranted. [7]. Donor livers with a median ASAT 1400 U/L, ALAT 1026 U/l. 
were accepted for OLT, showing a peak in transaminases on the day of surgery, but normalized 
in one week [30].  
3) Circulatory instability 
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Lucidi et al reported their risk factors as high vasopressor use, ICU stay > 4 days and BMI > 30, 
that were present in respectively 44%, 27%, and 16% of the donors. They failed to observe 
significant differences in initial graft function. Bad initial function (IPF + primary non function 
(PNF)), was in most cases associated with donor peak serum Na+ > 160 mEq/L and ICU stay > 
4 days (Odds ratios of 26.9 and 4.4, respectively). [11]. It is suggested that prolonged hypotension 
of the donor during ICU management have no significant increase in post-transplantation graft 
loss. However, graft loss was increased in liver transplant recipients, when donors received 
norepinephrine together with dopamine (dose >10 μg/kg/min) [28]. Temporary cardiac arrest 
might occur in any donor. Hoyer et al identified 77 donors with temporary cardiac arrest of 884 
OLTs after DBD. In the patient group with cardiac arrest, the median resuscitation time was 16.5 
minutes. There was no difference in patients and graft survival between the two groups. 
Multivariable analysis identified CIT as a risk factor for both patient and graft survival in these 
donors [31].  
4) Alcohol abuse, and infection 
Wu et al. [14] reported that in case of grafts from a donor with a positive culture there was no 
significant increase in adverse outcomes of the recipient. Mangus et al divided donors with a 
documented history of alcohol consumption into three groups according to duration of abuse 
(<10 years, 10-24 years and >25 years). Of the revised 1478 consecutive donors only 11% had 
alcohol abuse at all. Risk of 90-day graft loss for the three groups was: 0%, 3% and 2%, 
compared to 3% for all other donors (P = 0.62). Also there was no statistically significant 
difference up to 10 years post-transplant [32].  
5) Hypernatremia  
Hypernatremia is a common complication in brain death patients. Several reports have suggested 
donor hypernatremia to have negative effects on graft dysfunction and mortality [33-35]. There 
are reports about direct correlation between the serum sodium level of the donor and the post-
transplantation transaminase levels of the recipients, and EAD, as well as higher level of 
postoperative serum bilirubin [37, 38, 39]. Figueras et al. also noted that a donor plasma sodium 
level of >155 mmol/L was associated with higher rates of liver retransplantation and graft loss 
within 1 month after transplantation which would reflect severe cellular damage [35]. This is an 
accordance with the report of Totsuka et al. who found prolonged coagulation times, associated 
with poor graft outcomes [36,37]. In contrast, the correction of the donor serum sodium level to 
less than 155 mEq/L before organ procurement resulted in improved hepatic allograft survival 
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and function. Although the mechanism was not elucidated, the author considered that the 
primary cause of hepatocyte death and graft dysfunction was increased hepatocellular osmolality. 
Powner et al. suggested that extracellular water is translocated into the hepatocytes where it leads to 
increased intracellular osmolality and causes cellular swelling [38].  
Conversely, recent studies have found there to be no correlation between donor hypernatremia 
and graft function or loss. Tector et al. found that donor peak serum sodium > 170 mEq/L was 
not associated with graft loss or dysfunction [39]. Renz et al. who defined hypernatremia as a 
serum sodium level of > 155 mEq/L also found that hypernatremia did not influence graft 
survival [40]. Akoad et al. reported that the rate of PNF, early graft failure within 30 days and 1-
year patient and graft survival of recipients from donors with hypernatremia (> 160mEq/L) were 
similar those in recipients of grafts from donors with optimal sodium levels [41]. Cywinski et al. 
also showed that donor serum sodium levels of > 155 mEq/L did not affect the liver function 
tests (ASAT, ALAT, and total bilirubin), the length of ICU stay, and the length of hospital stay, 
early recipient survival or early graft function [42]. Mangus et al. found that severe donor 
hypernatremia (> 170 mEq/L) had a minor clinical impact on the ALAT level on post-transplant 
day 1, but no impact on early liver function or risk of failure, for up to 1-year after 
transplantation [43]. Goldaracena et al. reported that there was no significant difference in the 30-
day and 1-year mortality rates of the recipients of extremely marginal liver grafts from with a 
serum sodium concentration of > 155 mEq/L and the recipients of optimal-state grafts [44]. 
Khosravi et al. compared the ASAT, ALAT, INR, and kidney function at post-transplant day 5 in 
recipients from donors with terminal donor serum sodium concentration of 155 mEq/L or 
greater and recipients from donors with a terminal donor serum sodium concentration of less 
than 155 mEq/L and found no difference between the two groups of recipients [45]. In pediatric 
liver transplantation, Kaseje et al. showed that donor serum sodium levels of ≧ 150-μmol/L were 
not associated with increased rates of mortality, rejection, or early biliary or infectious 
complications. However they found that the prothrombin time on post-transplant day 10 was 
significantly lower in the hypernatremia group [46]. Uribe et al. performed five pediatric liver 
transplants from donors with hypernatremia. The serum sodium levels were 169 -193 mEq/L 
before medical management and between 157 and 172 mEq at procurement. One patient died 
from sepsis due to biliary complications and another patient suffered acute liver failure, and 
required a re-transplantation two weeks after the initial transplant. They suggested that 
hypernatremic donors may be used for pediatric LT under special circumstances [47]. In 
conclusion we can say that hypernatremia, less than 160 mEq/L is not an absolute 
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contraindication to accept a liver graft per se. However it is recommended to consider that an 
accumulation of risk factors might enhance their influence on the outcome. 
6) Donor liver steatosis 
Donor liver steatosis is a frequent finding during organ procurement. In the study of Briceno et al 
120 patients who underwent OLT for HCV cirrhosis were evaluated. In 66% of cases mild to 
severe donor steatosis was found.  Detailed results in the groups according to the degree of 
steatosis were the following: absent (0%-10%; n = 40), mild (10%-30%; n = 32), moderate (30%-
60%; n = 29), or severe (>60%; n = 19). Burra et al controlled 116 biopsies taken at the back table 
preparation, before implantation. No steatosis was seen in 50.9% of the biopsies, whereas 
steatosis was mild in 39.6% of the samples and moderate/severe in 9.5% of the samples. This 
was already reported by Busuttil et al in 2003 that hepatocytes are susceptible for ischemic 
reperfusion injury (IRI). During IRI many different pathophysiological pathways will be 
activated, for example activation of Kupffer cells and Ito cells, increasing production of free 
radicals, and reactive oxygen derivates. These processes will conclude to chemokine release, 
activation of polymorphonuclear cells, driving to an inflammatory-like cascade. This results in a 
decreased blood flow in the hepatic sinusoids. Diminished oxygen supply will lead to hepatocyte 
damage through apoptosis and necrosis, even in healthy livers. However this process will be 
much enhanced in steatotic grafts, where the microcirculation was already damaged by fat 
droplets and cellular oedema during cold ischemia.   [48]. 
Liver steatosis has a multifactorial etiology and it is commonly seen in diabetic and obese patients 
as well in patients with alcohol abuse.  Based on the histologic features liver steatosis can be 
classified as microvesicular or macrovesicular. Microvesicular steatosis appears as diffuse 
formation of small fat vacuoles surrounding the nucleus, it is usually associated with prolonged 
hospitalization and total parental nutrition, and sepsis, but in most cases it is reversible. 
Macrovesicular steatosis is characterized by a single fat vacuole larger that nucleus, which displace 
the nucleus to the periphery. It is usually associated with obesity, diabetes, hyperlipidaemia and 
alcohol abuse. Usually both micro- and macrovesicular steatosis is present simultaneously at 
different degrees. Steatosis can be graded (quantified) based on histology as mild (<30%), 
moderate (30%-60%) and severe (>60%).  Microvesicular steatosis has limited influence on post-
transplant liver graft function compared to macrovesicular steatosis, which is more often 
associated with graft dysfunction. Moreover, the grade of macrovesicular steatosis correlates with 
the incidence and severity of graft dysfunction.  
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The estimation of the grade of steatosis before and at the time of organ procurement remains 
challenging. Prediction of the degree of steatosis based on the clinical and biochemical 
parameters is difficult, however a recent study by Cucchetti et al.  showed that combination of 
BMI, elevation of ALAT, presence of type II diabetes mellitus, history of heavy alcohol 
consumption and ultrasonography signs of steatosis could accurately identify steatosis >30%, 
confirmed by liver biopsy [49]. A preliminary study evaluating the feasibility of transient 
elastography in the assessment of liver steatosis in potential deceased liver donors demonstrated 
promising results [50]. Even though the results of studies by Yersiz et al and Martins et al show 
good prediction of liver steatosis by the procuring surgeon based of gross appearance of the liver, 
especially if steatosis is <30%, liver biopsy remains the gold standard as an objective assessment 
of the degree of liver steatosis and it is recommended in any case of suspicion of steatosis [51-
56]. Nevertheless, a recent study by El-Badry et al. demonstrated significant intra-observer 
variability in the histologic assessment of liver steatosis among expert pathologists [57]. 
The impact of degree of liver steatosis in liver biopsy was studied by Sitzer et al. in 5051 donors in 
correlation with DRI [58]. Except for well-known factors from DRI such as donor age, CIT and 
DCD, donor liver macrovesicular steatosis was an additional factor that strongly associated with 
graft failure at 1 year after liver transplantation (LT). Steatotic livers have been reported to be 
more susceptible to cold ischemia injury and moderate to severe macrovesicular steatosis has 
been observed as the leading cause of severe liver preservation injury [3]. Others report about 
225 consecutive liver transplants that were reviewed according to the intraorgan blood flow in 
association with mild (<30%, and moderate/severe (>30%)) macrosteatosis of the donor liver. 
Angele MK et al report that organ blood flow was not affected by steatosis [59].  
The use of grafts with moderate steatosis (30%-60%) remains a challenging issue, since the 
incidence of primary non function may reach 15%, and the rate of delayed graft function 
approaches 35%. Except when procurement is performed by an experienced transplant surgeon, 
no graft should be rejected solely on the basis of inspection. Biopsy should be viewed as a means 
for transplanting more organs. Recipient selection and minimal CIT are paramount to the 
successful utilization of moderately steatotic allografts as a period of delayed allograft function is 
expected [7]. 
Allocation of the steatotic grafts in the recipient with HCV-related liver requires some caution. 
The results of current studies are not univocal. Although previous studies suggested exacerbation 
of HCV recurrence in patients transplanted with steatotic grafts this finding was confirmed only 
in by Briceno et al., who showed more frequent and earlier HCV recurrence in recipients of 
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moderately and severely steatotic grafts [60]. Two other studies demonstrated no impact of mild 
to moderate graft steatosis on HCV recurrence after LT [61,62]. Moreover, Burra et al. showed 
that even severe steatosis had no influence on progression to fibrosis in HCV+ recipients and on 
3-year patient survival [62]. In two Italian studies graft steatosis >25% was found to be 
independent risk factor for biliary complications, especially for biliary strictures after OLT,  
however there was no obvious explanation for this finding [63,64]. According to Subramanian et al 
steatosis significantly influences post OLT HCV specific immune response and development of 
allograft fibrosis. Increasing grades of steatosis favours the development of predominant Th 17 
type HCV specific immune response with concomitant suppression of Th1 (IFN-gamma) [65]. 
The Paris consensus meeting concluded that mild steatosis (30%) has minimal impact on liver 
function post-transplantation, provided that CIT is short [7]. As a previous ELTR analysis had 
identified a cut-off of CIT<12 hours [66], the current recommendation is to keep total ischemia 
time below 12 hours although the precise threshold for improved outcome is unclear [67]. Liver 
grafts from elderly donors and/or donors with steatosis are even more affected by prolonged 
CIT and preservation injury. In this group, optimal liver function can be best achieved when 
CITs are kept less than 8 hours [7]. The ELTR survey showed that 5-year recipient survival was 
57% with CIT over 15 hours versus 64% with CIT between 12 and 15 hours and 67% with CIT 
below 12 hours [68]. 
In cases of donors with any risk for a chronic liver disease (anti-HCV, alcohol abuse) the 
identification and grading of fibrosis is expected from a biopsy [7]. Estimation of steatosis using 
haematoxylin and eosin (H&E)-stained frozen section liver biopsy has been reported to be 
difficult and subjective [3]. Therefore the debate about whether and how to perform a biopsy is 
ongoing. To expedite allocation and minimize CIT, a uniformly recognized strategy for successful 
ECD utilization, histologic evaluation, is typically performed by local pathologists where 
donation occurs. A study designed to compare the results of frozen sections (FS) performed by 
local pathologists with the ones of permanent sections (PS) evaluated by experienced hepato-
pathologists. Its seems that comparing FS and PS the evaluation of fibrosis and necrosis 
exceeded 80% correlation, and the estimation of macrovesicular and microvesicular steatosis 
approximated 70% agreement. Agreement between FS reports by local pathologists at the donor 
hospital and PS evaluated by experienced hepatopathologists was high, and significant 
discrepancies were rare. This evaluation suggests that biopsy misinterpretation is unlikely and 
should not present a significant impediment to further ECD expansion and increased allograft 
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travel [53]. A prerequisite to better understand the impact of graft steatosis on outcome will be to 
obtain routine donor liver biopsy at the time of harvest [13]. 
In conclusion, the presence of steatosis in the donor liver graft is an independent and 
determinant risk factor for the postoperative graft function and outcome. Steatosis makes the 
hepatocytes susceptible to further injuries, like ischemia, or virus positive environment. While 
microsteatosis is not a risk factor per se, macrosteatosis, especially if this is moderate, or severe, 
graded by histology, can be a cause of graft failure. The gold standard of the diagnosis is the 
biopsy that is recommended in all doubtful cases.  
IV) Non-conventional factors of an Extended Criteria Donor 
This chapter briefly discuss „non-conventional” ECD. parameters. These are the hepatitis C and 
B infected grafts, and the donors after cardiac death. We call them non-conventional since they 
were not involved in the assessment of all (also non-ECD) donors earlier, and their 
implementation as a part of expanding the donor pool.. 
1) Hepatitis C and hepatitis B infected grafts 
Organ shortage provoked the transplant community to expand the donor pool with the 
hepatotrop virus positive donors. This is consent that HCV and HBV positive donors mean a 
higher risk in liver transplantation. On the other hand the largest population of recipients waiting 
for a liver is also the HVC/HBV positive patients. Thuss it is fair to discuss the assessment, and 
allocation of these donors. The reactivation / recurrence of HCV and HBV will be discussed in 
the second part of this review. 
a. Anti-HCV positive donors 
First, HCV+ donors were rejected due to the concerns of viral transmission and accelerated 
HCV recurrence. Preliminary reports have been published with short follow-ups and no 
differences in outcomes with the use of anti-HCV-positive grafts [69]. However, it has been 
clearly shown that the survival and progression of HCV disease is similar to HCV negative 
allografts [70]. Therefore, HCV+ grafts are increasingly used by transplant centres [71].  
In a study by Northup et al., data of 19,496 HCV positive recipients and 934 HCV positive 
donations were analysed using the US OPTN Scientific Registry database [72]. They have 
reported good long-term outcomes using HCV+ liver grafts, finding that mean survival times in 
HCV+ recipient / HCV+ donor was 9.8 years compared to 10.6 years for HCV+ 
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recipient/HCV- donor. In addition, after adjusting for factors known to affect post-transplant 
survival, the hazard ratio was equivalent for both groups [72].  
Similar conclusions have been made by Burra et al. in 2011 after analysing the UNOS database 
including 63,149 liver transplants (61,905 donors HCV-; 1,244 donors HCV+) from 1987 to 
2007. In the case-controlled matched cohort, HCV status was shown to have no significant effect 
on overall mortality or graft survival. It should be mentioned that nearly one-third of HCV+ 
allografts were transplanted into HCV - recipients (30.7%) in this study, concluding a potential 
benefit of HCV+ allografts in certain circumstances and recipients (acute liver failure or extreme 
illness without a correspondingly appropriate MELD score) [71].  
In a European multicentre study by Ballarin et al. data of 694 patients with HCV-related cirrhosis 
were analysed. They also found that the use of anti-HCV-positive donor was not a significant risk 
factor regarding patient and graft survival for HCV positive patients. However, recipients of anti-
HCV-positive donor grafts had a higher incidence and histology-proven recurrence of hepatitis C 
than HCV-/HCV+ group, although it did not reach statistical significance (P=0.07). Further it 
has been also shown that HCV-RNA positivity likely represents a predictive factor for 
development of recurrent hepatitis C after transplantation, such as steatosis and aging [69].  
It has been reported by O'Leary et al that 53% (17/32) of HCV seropositive donors are HCV-
RNA negative. Although in only a small number, it has shown that graft and patient survival, as 
well as fibrosis progressions were unchanged in recipients of viremic and aviremic donors. 
Another finding was that patients infected with non-1 genotypes would have a disadvantage if 
they are given a genotype 1 infected graft and genotype 1 dominated. They also suggested to 
allocate HCV antibody-positive donors to genotype 1 infected recipients at this time [73]. 
In conclusion, the use of HCV+ grafts for HCV+ recipients is comparable in outcome even in 
the long-term. Behind these findings a potential role of the relatively large proportion of HCV 
seropositive but HCV RNA negative liver grafts could be mentioned. It seems that the leading 
risk factor for recurrence of hepatitis C with an anti-HCV-positive graft is HCV-RNA positivity. 
The allocation of HCV-seropositive donors to genotype 1 infected patients could be suggested. 
b.  Anti-HBc positive donors 
The major limitation to using liver grafts from HBV core antibody-positive (anti-HBc) but HBV 
surface antigen (HBsAg) negative donors is the potential risk of de novo HBV infection after 
transplantation [74]. However, an overall low risk of HBV reactivation has been shown when 
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treated with nucleos(t)ide analogues and hepatitis B immunoglobulin (HBIG), therefore, anti-
HBc positive grafts are no longer rejected in many transplant centres [75,76]. In HBV related 
cirrhosis, anti-HBc donors are frequently used as they require life-long anti-HBV prophylaxis in 
any case and postOLT outcomes have not been affected [74]. Allocation policy and prophylactic 
protocols are the main issues in this field.  
In a study by Yu et al. [77], similar survival rates have been shown in recipients with anti-HBc 
positive grafts in comparison to the ones with anti-HBc negative grafts. The use of anti-HBc 
positive grafts appeared to affect recipients without anti-HBs more adversely than those with 
anti-HBs prior to OLT [77]. A prospective multicentre study by Angelico et al. showed that the 
use of anti-HBc positive donor grafts is associated with excellent results when they are 
transplanted to HBsAg positive recipients, receiving standard prophylaxis against HBV. 
Conversely, the use of anti-HBc positive donor grafts in HBsAg negative recipients requires 
attention, as it may be associated with suboptimal survival, especially in patients with high 
MELDs and/or additional risk factors. The presence of anti-HBc in HBsAg negative recipients 
does not seem to be protective and cannot justify the allocation of anti-HBc positive donor grafts 
to these patients [78]. MacConmara et al [79] reported similarly good results. All but one of the 
HBcAb+ organ recipient deaths occurred in patients with MELD scores of >30 at 
transplantation and the difference was apparent when this group was compared with HBcAb+ 
organ recipients with lower MELD scores, and also when it was compared with control 
recipients with MELD scores >30. None of their patients had de novo HBV infection during 
study period using prophylaxis with HBIG for 3 months and subsequently provide lifetime 
antiviral therapy.  
Brock et al. evaluated 958 HBsAg negative recipients of anti-HBc positive donors. Patients were 
classified on the basis of whether they received HBIG alone, Lamivudine alone, both, neither, or 
were missing this information. They observed that HBIG-only therapy had improved patient 
survival relative to Lamivudine only prophylaxis. Similarly, improved graft survival was observed 
for HBIG vs. Lamivudine-only recipients, though the result was not statistically significant. The 
combination therapy group (HBIG and Lamivudine) was also observed to have longer patient 
survival relative to Lamivudine-only therapy [80]. 
Loggi et al. reported that the use of HBsAg positive grafts is a safe procedure with appropriate 
antiviral therapy. 10 patients were studied using HBsAg positive grafts for OLT in patients with 
serological evidence of past hepatitis B infection.  None of the patients developed any sign of 
HBV-related disease compromising the graft or patient survival. In addition, they noticed that 
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HBsAg positive patients, even when treated with nucleos(t)ide analogues and HBIG were unable 
to clear the virus. Conversely, patients who previously controlled HBV, even in the case of 
HBsAg reappearance, were able to control it again [76].  
In a review paper by Skagen et al. analysing 26 studies including the risk of de novo hepatitis B 
from HBcAb positive donors, found that the rate of de novo hepatitis B was the highest for 
HBV naïve recipients of anti-HBc positive liver donors. They have recommended utilizing long-
term lamivudine alone in recipients who are HBV naïve and have isolated anti-HBs. Recipients 
with anti-HBc positivity should not be offered prophylaxis but should undergo close virologic 
and serologic surveillance with monitoring of HBV DNA, HBsAg, and liver enzymes [81].  
In conclusion, liver grafts from anti-HBc positive donors should be allocated to recipients with 
prior HBV exposure. The presence of anti-HBs seems to protect from de novo HBV infection 
and both anti-HBc and anti-HBs positive recipients seem to represent a group that can safely 
receive anti-HBc positive liver grafts without any post-transplant HBV prophylaxis [74]. 
According to MacConmara et al liver transplantation using HBcAb+ grafts can be performed 
with similar outcomes to transplants that use HBcAb- grafts. [79].  
2) Donors after cardiac death 
The first human LTs were performed from donation after cardio-circulatory death (DCD) in the 
1960s [82]. In the United Kingdom, liver transplantation after DCD organs has increased steadily 
over the last few years and now accounts for 20% [83]. DCD is based on cardiopulmonary 
criteria for death rather than neurologic criteria, when WIT is typically prolonged [70]. The use of 
these liver grafts has been associated with higher rates of graft failure and biliary complication, 
particularly ischemic type cholangiopathy, compared with donation after brain death (DBD) 
allografts [84]. Optimum outcome has been shown if the WIT does not exceed 30 minutes, the 
CIT is limited to less than 8 hours, and younger donors being used (<50 years)[71]. Nguyen et al. 
examined long-term outcomes in 19 DCD donors, 234 standard criteria donors (SCD) and 214 
ECD donations. Evaluating these results we have to take the smaller case number of the DCD 
group into account. They found no difference in the rate of primary non-function and biliary 
complications comparing DCD with SCD and ECD. The overall one, two-, and five-years DCD 
graft and patient survival was 73.7%, 68.4%, and 63.2%, and 89.5%, 89.5%, and 89.5%, 
respectively. DCD graft survival was similar to graft survival of SCD and ECD in non-hepatitis C 
virus (HCV) recipients (p > 0.370). In contrast, DCD graft survival was significantly reduced in 
HCV recipients [85].  Skaro et al reports about 32 DCD and 237 SCD donations. In their findings 
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DCD livers had a 2.1 times greater risk of graft failure, a 2.5 times greater risk of relisting, and a 
3.2 times greater risk of retransplantation compared with DBD recipients. DCD recipients had a 
31.6% higher incidence of biliary complications and a 35.8% higher incidence of ischemic 
cholangiopathy [86]. A large US study by Mathur et al. reported good outcomes using DCD grafts. 
Three years post-DCD liver transplant, 64.9% of recipients were alive with functioning grafts, 
13.6% required retransplant and 21.6% died. They have shown that each hour increase in CIT 
was associated with 6% higher graft failure rate (OR 1.06, p < 0.001) and donor WIT ≥ 35 min 
significantly increased graft failure rates (OR 1.84, p = 0.002). Recipient predictors of mortality 
were age ≥ 55 years, hospitalization at transplant and retransplantation (all, p ≤ 0.006). Donor 
weight >100 kg and CIT also increased patient mortality (all, p ≤ 0.035) [87].  Abou Abbass et al 
reported a high prevalence of biliary complications with a new and wide spectrum of 
clinicopathologic findings about 26 DC OLTs in 2010. Biliary complications occurred in 46%, 
and retransplantation rate was 23% [88].  Bartlett et al reported 14 pediatric cases with DCD 
grafts. Livers were transplanted as a whole organ (4), reduced graft (8), formal split (1) or auxiliary 
transplant (1). Compared to DBD recipients ASAT was significantly higher on the first three 
post-operative days and there was no difference in the INR, bilirubin or γGT out to 12 months. 
There were no biliary or vascular complications and patient and graft survival is 100% at a 
median follow-up of 41.8 months (1.7-74 months) [89].  
a. HCV recurrence and DCD donation 
Although in limited number, recent studies aimed to examine the impact of DCD use on the 
outcome of OLT in HCV positive patients. The summarized results are shown in Table 2.  
Yagci et al analysed data of 14 DCD/HCV and 188 DBD/HCV patients and reported a 
significantly lower overall patient and graft survival rate for DCD patients compared to the DBD 
patient group. In addition, the incidence of liver abscess with ischemic-type biliary stricture was 
higher in recipients from DCD as compared with DBD (42% vs 2%). The incidences of hepatic 
artery thrombosis (HAT), portal vein thrombosis, and PNF were similar between the DCD and 
DBD groups [90]. Tao et al. examined the impact of DCD livers on patient and graft survival in 
HCV infected patients and compared the severity of their HCV recurrence to that of matched 
group of patients who received DBD livers. DCD patients had significantly higher peak ASAT 
and ALAT levels in the early postoperative period suggesting a higher probability of 
ischaemia/reperfusion injury in the DCD grafts. Despite these findings no difference was found 
in DCD vs DBD groups regarding time and severity of HCV recurrence (postoperative HCV 
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RNA levels, SVR rate, HCV-related graft failure leading to retransplantation or death, 4/6 
fibrosis.) [91].  
In a paper by Mawardi at al. graft outcomes in HCV and non-HCV liver transplant recipients of 
DCD grafts were analysed. A lower rate of biliary complication was seen in the HCV group when 
compared with the non-HCV group (p = 0.21). An excellent patient and graft survival was 
observed in the non-HCV recipients of DCD grafts (100 and 92%, respectively) compared to (78, 
67%) in HCV recipients.  The 33% (3/9) of the HCV recipients of DCD grafts suffered graft 
loss, two from fatal aggressive fibrosing cholestatic (FCH) HCV and one due to ischemic 
cholangiopathy [92].  Similarly to previous authors, Hernandez-Alejandro et al. found DCD graft 
as a risk factor for earlier and more aggressive HCV recurrence as revealed in the finding that 
47% of our HCV recipients of DCD grafts were documented to have significant fibrosis (stage 2) 
within the first transplant year compared with a significantly smaller number (10%) in the 
matched control group.  When comparing HCV DCD recipients with HCV DBD recipients, a 
significant decreased graft survival, higher rate of HCV recurrence at 3 months and an increased 
rate of severe HCV recurrence within the first year were found. Protocol biopsies performed in 
HCV DCD liver transplant recipients showed histologic progression from time 0 to 3 months 
and then 1year, lending support that this was due to HCV progression and not a static process 
secondary to ischemia/reperfusion damage obtained at the time of liver procurement [93]. 
In contrast, Taner et al reported similar graft and patient survival rates of HCV patients regardless 
of the graft type that they received and concluded an advantage of DCD graft utilization in HCV 
patients, and only the MELD score at the time of OLT and CMV infection within the first 
postoperative year affected graft survival. Among the factors studied for fibrosis progression, 
HCV genotype 1 was as a significant factor, whereas moderate to severe acute rejection episodes 
within the first year approached statistical significance. It should bet noticed that in this centre 
donors older than 60 years have not been used for HCV patients. As such, HCV patients are 
limited to younger donors, so their waiting times are longer than those of patients with other 
etiologies of liver disease. As a result, DCD grafts were used more often in HCV patients (51%) 
compared to overall percentage of HCV patients in our program (35%) [94] . 
UNOS data analyses regarding HCV recurrence and DCD donation have been reported by 
Uemura et al. in 2012. DCD liver transplantation achieved inferior graft survival compared to 
DBD donor transplants regardless of HCV and non-HCV status and the difference in graft 
survival between DCD donor and DBD donors was significantly less in HCV patients compared 
to non-HCV patients. One possible explanation for their finding was the effect of a younger age 
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for DCD donors. A favourable outcome can be expected if a DCD liver is transplanted in a 
favourable condition, meaning WIT less than 30 minutes, CIT less than 8–10 hours, and donor 
age less than 50–60 years. However, due to the lack of recurrent HCV data (liver biopsy and 
HCV PCR), firm conclusions regarding HCV recurrence after DCD donation could not been 
made [95].  
b. DCD donation and additional ECD factors 
Earlier, DCD was defined as an independent factor itself. Therefore the common policy was not 
to combine DCD with other ECD factors. However Tariciotti L et al focused on DCD liver grafts 
in their series where “extended” criteria were applied (donor age > 60 yrs., BMI>30, donor WIT 
>30 min., CIT > 8 hours).  The 1-year patient and graft survival was 88% and 82% for the 
standard group vs. 90% and 90% for the extended one. The rate of biliary complications did not 
differ [96]. The dilemma between diminishing the WLM and putting the recipients on a higher 
risk of graft failure will then be complicated by the question: on what price? Broomhead HD et al 
focused on the need of perioperative resources in case of DCD OLTs: the increased prevalence 
of reperfusion syndrome (P < 0.001), a prolonged heparin effect (P = 0.01), a greater incidence 
of hyperfibrinolysis (P = 0.002), longer periods of postoperative ventilator use (P = 0.03), and 
vasopressor support (P = 0.002), and a prolonged ICU of stay (p = 0.02).was characteristic to 
DCD group. Together with an overall poorer quality of DCD grafts, their advice is then to regard 
on donation after brain death (DBD) as a first resort [83] 
The term ‘controlled’ and ‘uncontrolled’ for DCDs were not used at the Maastricht workshop 
but added later. For the uncontrolled DCD donor, death was either confirmed outside of hospital 
(Maastricht I) but the donor was still brought to hospital; or death was declared after 
unsuccessful resuscitation after witnessed cardiac arrest (Maastricht II) usually in the Accident 
and Emergency unit [97]. The Maastricht type II DCD (sudden- out-hospital cardiac arrest) 
uncontrolled donation increases donor risk extremely, and makes it impossible to carry out a 
safety procedure in the majority of the cases. Fondevilla et al revised 400 potential M-II donors of 
whom only 34 liver transplants were performed (9%), with one-year recipient and graft survivals 
of 82% and 70%, respectively [98].  
In a recent and large study based on the UNOS/OPTN database, 85148 patients were found to 
receive a liver graft from a DBD, and 2351 from a DCD procedure. Cumulative survival was 
significantly worse for DCD, but only in adults. Pediatric recipients had similar survival in both 
groups. The optimal value for risk factors were recipient age <50 yrs., INR< 2,0, albumin > 3,5 
D
ow
nl
oa
de
d 
by
 [D
eb
rec
en
 U
niv
ers
ity
] a
t 0
6:2
9 0
3 F
eb
ru
ary
 20
16
 
19 
 
mg/dL, CIT < 8 hours, and donation WIT <20 min [99]. Jay CL et al studied the comparative 
effectiveness of DCD vs. DBD OLT. A Markov model was constructed to compare undergoing 
DCD transplantation with remaining on the wait-list until death or DBD liver transplantation. 
DCD liver transplantation resulted in inferior survival for patients with a MELD score <15 and 
HCC patients receiving MELD exception points, but provides a survival benefit to patients with 
a MELD score >20 and to HCC patients without MELD exception points. The incremental 
cost-effectiveness ratio (ICER) was >$2,000,000/quality-adjusted life years (QALY) for 
MELD<15, and $478,222/QALY and $120,144/QALY, for MELD 21-30, and over 30, 
respectively. [100]. In summary the recent experience with controlled donation after cardiac death 
are encouraging. However, in this context, other risk factors (old age, CIT, WIT, steatosis) for 
graft failure should be avoided. Recent data regarding the use of these grafts in HCV patients are 
somewhat controversial. One potential explanation for worse outcomes in HCV could be the 
higher susceptibility to ischemic injury and cellular proliferation as a consequence. 
V) Expert commentary 
Optimal utilization of ECD liver grafts is based on the best estimation of liver quality, proper 
recipient selection, management to minimalize the travel injury, avoidance of further surgical fails, 
and a high quality ICU care of the recipient. An ideal recipient group for donors > 70 years has 
been described as patients > 45 years old, with body mass index <35; non-HCV+,  non-UNOS 
status 1 registration; first transplants with a CIT < 8 hours.  OLT using grafts showing 
microvesicular steatosis seems to be safe regardless of its severity, while the outcome of OLT 
with macrosteatotic grafts depends on the severity of the fat infiltration. McCormack et al. showed 
that LT with grafts with steatosis > 60%, (despite the higher incidence of EAD) can achieve 
excellent patient and graft survival when these grafts are allocated in low risk recipient [101]. The 
proper allocation of steatotic grafts was confirmed by Dutkowski et al., who analysed the two 
largest liver transplant databases in Europe and in the US. Graft with <30% steatosis can be used 
safely up to BAR (Balance of Risk) score of 18 or less, however if graft steatosis exceeds 30% 
acceptable outcome can be achieved only if BAR score is less than 9 score [102]. Also the use of 
low score ECDs in recipients with moderate cirrhosis and HRS is a good option. However, grafts 
from moderate-to-severe steatosis and those from aged donors must be carefully allocated in 
candidates with HRS. Allocation of some marginal donors may not cause any debate: HCV+ 
livers must be transplanted to HCV+ recipients and anti-HBc+ grafts must be initially 
transplanted to HBV+ patients, but may be transplanted to HBV-negative recipients provided 
antiviral therapy is used after transplantation.  Allocation systems have different dimensions: for 
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example.an extra regional sharing in Eurotransplant represents much less distance in comparison 
with United States. A formula to calculate the DRI was developed. It includes only donor and 
transplant parameters found to significantly influence outcomes after liver transplantation in a 
multivariate analysis of a large cohort (20,023 transplants) from the Scientific Registry of 
Transplant Recipients database. These parameters are as follows: the donor’s age, race, height, 
and cause of death; the split liver donation status; the DCD status; the type of allocation (local, 
regional, or national); and the CIT. The mean DRI was remarkably higher in the Eurotransplant 
region versus OPTN (1.71 versus 1.45), and this indicated different donor populations [19].  
Regarding the non-liver field of transplantation, HCV positive donors are also used in kidney 
transplantation, with promising results. Analysing more than 1600 kidney transplantations, Scalea 
et al found that R+/D+ patients spent less time on the transplant waitlist, which contributed to 
improved death censored graft survival when compared with R+/D- patients (103). Others 
found that patients receiving ECD transplants had lower allograft survival after seven years than 
patients receiving transplants from standard criteria donors (SCD; 80% v 88%, P<0.001). 
Analysing 6890 patients they concluded that of the 916 used, CED kidney, the circulating DSA, 
and prolonged CIT (>12hours) were the main composites for an ECD in kidney transplantation 
(104). This is clear that measures for an ECD are different in liver and kidney transplantation. 
This is common that donor age, and HCV/HBV positivity are not absolute limiting factors any 
more. Organ specific influencing factors are the donor specific DSA for kidney, and the steatosis 
for liver transplantation. This is typical to all organ transplant programs that the combination or 
cumulative presence of certain factors will increase the risk of graft failure significantly. Therefore 
the suggested pathway of organ quality assessment consists of three steps: obtain the most 
information  (e.g. biopsy in questionable cases), consider that co-existing factors can potentiate 
each other (e.g. a 56 year old HCV positive donor, with an increased Na+, and enlarged liver on 
ultrasound), and finally to consider the potential homeostatic reserves capacity of the recipient 
(e.g. an ECD liver can be fit for a patient with an HCC, without severe cirrhosis, but not for an 
acute liver failure). As a fourth factor a surgeon always should take into account that additive 
technical problems might worsen the situation. Therefore an ECD liver graft with an anatomical 
variation or injury that requires reparation will increase the risk additive complications like arterial 
thrombosis.   
VI) Five Year View 
In the next five years, it is anticipated that the use of HCV positive donors will be widely 
accepted for HCV positive recipients. The use of HBV positive donors will not be restricted to 
HBV positive, but also to HBV negative candidates with a proper nucleoside treatment. 
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Hypernatremic donors may be useful for liver transplantation in the countries around the world 
that are affected by organ shortages. The development of ICU management will open this narrow 
pathway together with the usage of machine perfusion that is going to be discussed later. 
Additionally, online evaluation of liver-graft biopsies will be organized through a 24hour service 
in proper centres to improve the utilisation of steatotic grafts, by ruling out macrosteatosis. The 
upper age limit will be pushed fowards together with the extension of old for old programs. Old- 
but otherwise good donor organs will be allocated regionally, to diminish other factors.Regarding 
the open network of the internet, patient consent to use an ECD will be a hot topic in the next 
five years. 
VII) Key issues 
1) Donor Risk Index has the most relevant association with the majority of outcome 
parameters, as it is validated by ELITA based on OPTN (UNOS) parameters.  
2) Donor age, and elevated liver function tests are not absolute contraindications. Biological 
age might differ from administrative one. The management of donor on the ICU have more 
impact on later results.  
3) Donor liver steatosis is a real challenge to assess. The ideal position is to have the biopsy 
and histology in the actual „tool kit”. Macrovesical steatosis is an independent risk factor for graft 
failure. It is a relative contraindication to OLT if its grade is moderate, or severe, Microsteatosis 
might also be a risk factor, when it is 20% or more. When histology cannot be performed other 
parameters must be considered as parallel or additive risk factors. Steatotic livers should not be 
transplanted to HCV/HBV positive or kidney function impaired recipients 
4) Hepatitis C and B positive donors can be used safely for HCV/HBV positive recipients. 
It seems that the leading risk factor for recurrence of hepatitis C with an anti-HCV-positive graft 
is HCV-RNA positivity. The allocation of HCV-seropositive donors to genotype 1 infected 
patients seems to be safe and also an effective way to expand the donor pool.   
5) Hypernatremic donors were previously considered as ECDs, because high serum sodium 
levels have been associated with decreased graft survival and function. It was thought that 
decreased graft survival and function were caused by cellular swelling, which occurs as a result of 
transition from an extracellular hypernatremic state to intracellular osmolality, these phenomenon 
lead to poor results. However, recent studies have revealed that hypernatremia is not correlated 
with graft survival and function. 
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Table 1. Milestones in the definiton of ECD 
 Barshes  (2007) [2] Nickkholgh. (2007) 
[3] 
Northup. (2007) [4] Burroughs (2009) 
[16] 
Blok (2012) [20] Bruzzone (2013) [21] Feng S (2014) [8] 
Donor ICU   ICU stay and 
ventilation support>7 
days, 
on vasopressors hospital stay >5 
days,  
ICU  stay >7 days;   ICU stay with 
ventilation > 7 days   
 
BMI >30 >30  high BMI >30 height /weight 
Donor cause 
of death 
anoxia, CVA  or other non-
trauma cause)  
 anoxia, CVA    anoxia, CVA 
Donor race 
and age 
black donor ≥60 years of age donor age>65 yrs black donor of any age donor age >55 yrs  donor age > 65 
yrs 
age up to 80 yrs black race, and 
age>60 
Steatosis  biopsy proven 
steatosis>40%, 
steatosis>40%  steatosis (not 
specified) 
steatosis   
serum Na+ peak serum Na+>165 
mmol/l, 
elevated serum Na  hyperNa (not 
specified) 
serum Na >165 
mmol/L  
 
Liver 
function tests 
ALAT /ASAT>3x 
normal, serum 
bilirubin>3mg/dL, 
elevated serum 
bilirubin 
 elevated 
ASAT/ALAT and 
se. bilirubine (not 
specidfed) 
ASAT >90 U/L, ALAT 
>105 U/L 
serum bilirubin >3 
mg/dL 
 
HCV/HBV 
serology 
positive serology for 
viral hepatitis  
     
Graft type split liver/ partial liver from a 
donor that is ≥40 years of age; 
or <40 years of age and black;  
     all split liver grafts 
DCD donation after cardiac death 
(DCD) together with any of the 
following: (≥40 years of age; 
<40 years of age and black; or 
<40 years of age and whose 
COD was either anoxia, CVA 
or other non-trauma cause 
 any DCD    any DCD 
Allocation CIT > 12 hours   CIT >12 h, and 
WIT >40 min 
  Regional/ national; 
and CIT 
Other donor 
factors 
 sepsis, meningitis, 
history of extrahepatic 
malignancy, previous 
drug abuse. 
6 months history of 
alcohol and/or 
cocaine dependency, 
malignancy, diabetes 
mellitus 
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